Divesiran (SLN124) - (SANRECO)

August 10, 2026: Silence Therapeutics plc (NASDAQ: SLN) reported positive topline Phase 2 SANRECO results for divesiran in 48 phlebotomy-dependent polycythemia vera patients. In the 36-week randomized, double-blind, placebo-controlled portion, divesiran met the primary endpoint: 88% of treated patients achieved response versus 19% on placebo (placebo-adjusted 69%; p<0.0001), with response defined as no phlebotomy and hematocrit below 45% during weeks 18-36. By dose, response rates were 93.8% for every-6-weeks dosing and 81.3% for every-12-weeks dosing.

The key secondary endpoint was also met: mean phlebotomies per patient during weeks 0-36 were 0.2 for divesiran versus 2.1 for placebo (p<0.0001). The company also reported improvements in hematocrit control, ferritin and other iron markers, and MPN-SAF Total Symptom Score.

Divesiran was described as well tolerated, with no new safety findings; injection-site reactions were infrequent and self-limiting, and there were two grade 1 anemia adverse events. All patients have completed the placebo-controlled portion and are in extension periods.

Upcoming catalysts: full Phase 2 SANRECO results are planned for presentation at an upcoming medical congress, and a Phase 3 PV trial of divesiran every 12 weeks versus placebo is anticipated to start in 1H 2027.